Hot Features
プレミアム
Vertex Pharmac Dl 01 (1VRTX)
BIT
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -828.00 | 364.25k | Automatic Disposition | 439.91 | 19.96k | -3.98% |
| 2026-05-29 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1.97k | 888.30k | Automatic Disposition | 450.00 | 22.76k | -7.98% |
| 2026-05-15 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -33.00 | 14.96k | Automatic Disposition | 453.45 | 7.28k | -0.45% |
| 2026-05-15 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1.35k | 613.97k | Automatic Disposition | 453.45 | 24.73k | -5.19% |
| 2026-05-12 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -6.99k | 3.14M | Automatic Disposition | 450.00 | 26.09k | -21.13% |
| 2026-05-01 | Mr. Suketu P. Upadhyayインサイダー | -796.00 | 0.00 | Sale to Issuer | - | 1.56k | -33.81% |
| 2026-05-01 | Ms. Nancy A. ThornberryIndependent Director | -398.00 | 0.00 | Sale to Issuer | - | 1.64k | -19.56% |
| 2026-05-01 | Dr. Jennifer SchneiderIndependent Director | -796.00 | 0.00 | Sale to Issuer | - | 922.00 | -46.33% |
| 2026-05-01 | Ms. Diana Lynne McKenzieIndependent Director | -796.00 | 0.00 | Sale to Issuer | - | 1.64k | -32.65% |
| 2026-05-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -1.10k | 469.22k | Automatic Disposition | 425.02 | 20.73k | -5.06% |
| 2026-05-04 | Dr. Sangeeta N. BhatiaIndependent Director | -318.00 | 134.75k | 売り | 423.73 | 3.98k | -7.40% |
| 2026-04-01 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -978.00 | 439.29k | Automatic Disposition | 449.17 | 21.83k | -4.29% |
| 2026-03-27 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2.33k | 1.05M | Automatic Disposition | 450.95 | 33.08k | -6.58% |
| 2026-03-13 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2.33k | 1.12M | Automatic Disposition | 481.79 | 35.41k | -6.17% |
| 2026-03-11 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2.63k | 1.31M | Automatic Disposition | 498.42 | 12.49k | -17.41% |
| 2026-03-04 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2.44k | 1.16M | Automatic Disposition | 475.30 | 15.12k | -13.88% |
| 2026-03-02 | Ms. Joy LiuEVP, Chief Legal Officer & Corporate Secretary | -892.00 | 442.40k | Automatic Disposition | 495.96 | 22.81k | -3.76% |
| 2026-02-27 | Dr. Reshma KewalramaniCEO, President & Director | -40.00k | 19.74M | Automatic Disposition | 479.75 - 496.95 | 98.28k | -28.93% |
| 2026-02-27 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2.33k | 1.12M | Automatic Disposition | 480.31 | 37.73k | -5.81% |
| 2026-02-26 | Ms. Kristen C. AmbroseSenior VP & CAO | -357.00 | 172.56k | Automatic Disposition | 483.36 | 6.62k | -5.11% |
| 2026-02-24 | Mr. Charles F. WagnerExec. VP, COO & CFO | -1.74k | 846.03k | Sale to Issuer | 485.11 | 27.72k | -5.92% |
| 2026-02-25 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -260.00 | 126.45k | Automatic Disposition | 486.35 | 29.50k | -0.87% |
| 2026-02-24 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -1.63k | 789.27k | Sale to Issuer | 485.11 | 29.50k | -5.23% |
| 2026-02-25 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -1.85k | 897.80k | Automatic Disposition | 486.35 | 65.75k | -2.73% |
| 2026-02-24 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -1.52k | 736.40k | Sale to Issuer | 485.11 | 65.75k | -2.26% |
| 2026-02-25 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -4.91k | 2.39M | Automatic Disposition | 486.35 - 489.00 | 17.56k | -21.85% |
| 2026-02-24 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -873.00 | 423.50k | Sale to Issuer | 485.11 | 17.56k | -4.74% |
| 2026-02-24 | Dr. Jeffrey Marc LeidenExecutive Chairman | -3.55k | 1.72M | Sale to Issuer | 485.11 | 35.24k | -9.15% |
| 2026-02-24 | Dr. Reshma KewalramaniCEO, President & Director | -4.98k | 2.42M | Sale to Issuer | 485.11 | 94.58k | -5.00% |
| 2026-02-25 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -620.00 | 301.54k | Automatic Disposition | 486.35 | 7.28k | -7.84% |
| 2026-02-24 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -582.00 | 282.33k | Sale to Issuer | 485.11 | 7.28k | -7.40% |
| 2026-02-24 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1.45k | 704.86k | Sale to Issuer | 485.11 | 40.06k | -3.50% |
| 2026-02-25 | Mr. Jonathan Billerインサイダー | -945.00 | 459.60k | Automatic Disposition | 486.35 | 13.66k | -6.47% |
| 2026-02-24 | Mr. Jonathan Billerインサイダー | -1.14k | 554.97k | Sale to Issuer | 485.11 | 13.66k | -7.73% |
| 2026-02-25 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -668.00 | 324.88k | Automatic Disposition | 486.35 | 18.43k | -3.50% |
| 2026-02-24 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1.63k | 789.27k | Sale to Issuer | 485.11 | 18.43k | -8.11% |
| 2026-02-25 | Ms. Kristen C. AmbroseSenior VP & CAO | -223.00 | 108.46k | Automatic Disposition | 486.35 | 6.98k | -3.10% |
| 2026-02-24 | Ms. Kristen C. AmbroseSenior VP & CAO | -546.00 | 264.87k | Sale to Issuer | 485.11 | 6.98k | -7.25% |
| 2026-02-19 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -48.51k | 14.37M | Derivative Exercise and Sale | 155.57 - 470.54 | 69.12k | - |
| 2026-02-19 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -10.11k | 4.76M | Automatic Disposition | 470.54 - 471.43 | 69.12k | -12.76% |
| 2026-02-17 | Mr. Charles F. WagnerExec. VP, COO & CFO | -2.29k | 1.11M | Sale to Issuer | 483.75 | 23.49k | -8.90% |
| 2026-02-17 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -977.00 | 472.40k | Automatic Disposition | 473.68 - 489.46 | 28.02k | -3.37% |
| 2026-02-17 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -2.29k | 1.11M | Sale to Issuer | 483.75 | 28.02k | -7.57% |
| 2026-02-17 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -2.14k | 1.04M | Sale to Issuer | 483.75 | 79.23k | -2.63% |
| 2026-02-17 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -1.15k | 555.35k | Sale to Issuer | 483.75 | 23.34k | -4.69% |
| 2026-02-18 | Dr. Jeffrey Marc LeidenExecutive Chairman | -2.96k | 1.43M | Sale to Issuer | 483.75 | 29.77k | -9.05% |
| 2026-02-17 | Dr. Reshma KewalramaniCEO, President & Director | -6.55k | 3.17M | Sale to Issuer | 483.75 | 89.26k | -6.84% |
| 2026-02-17 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -3.62k | 1.75M | Automatic Disposition | 473.68 - 489.46 | 8.49k | -29.90% |
| 2026-02-17 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -1.11k | 536.96k | Sale to Issuer | 483.75 | 8.49k | -11.57% |
| 2026-02-17 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -1.91k | 924.93k | Sale to Issuer | 483.75 | 41.52k | -4.40% |
| 2026-02-17 | Mr. Jonathan Billerインサイダー | -3.72k | 1.80M | Automatic Disposition | 473.68 - 489.46 | 15.75k | -19.11% |
| 2026-02-17 | Mr. Jonathan Billerインサイダー | -1.51k | 728.04k | Sale to Issuer | 483.75 | 15.75k | -8.72% |
| 2026-02-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -2.85k | 1.38M | Automatic Disposition | 473.68 - 489.46 | 20.73k | -12.08% |
| 2026-02-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1.53k | 740.14k | Sale to Issuer | 483.75 | 20.73k | -6.87% |
| 2026-02-17 | Ms. Kristen C. AmbroseSenior VP & CAO | -2.20k | 1.06M | Automatic Disposition | 473.68 - 489.46 | 7.75k | -22.07% |
| 2026-02-17 | Ms. Kristen C. AmbroseSenior VP & CAO | -598.00 | 289.28k | Sale to Issuer | 483.75 | 7.75k | -7.16% |
| 2026-02-13 | Mr. Charles F. WagnerExec. VP, COO & CFO | -4.57k | 2.23M | Sale to Issuer | 487.76 | 23.42k | -16.32% |
| 2026-02-13 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -1.50k | 749.99k | Automatic Disposition | 499.99 | 26.55k | -5.35% |
| 2026-02-13 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -3.80k | 1.86M | Sale to Issuer | 487.76 | 26.55k | -12.53% |
| 2026-02-13 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -3.55k | 1.73M | Sale to Issuer | 487.76 | 75.58k | -4.48% |
| 2026-02-13 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -2.28k | 1.11M | Sale to Issuer | 487.76 | 19.53k | -10.47% |
| 2026-02-13 | Dr. Reshma KewalramaniCEO, President & Director | -13.04k | 6.36M | Sale to Issuer | 487.76 | 133.49k | -8.90% |
| 2026-02-13 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -2.28k | 1.11M | Sale to Issuer | 487.76 | 10.63k | -17.68% |
| 2026-02-13 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -3.80k | 1.86M | Sale to Issuer | 487.76 | 38.05k | -9.09% |
| 2026-02-13 | Mr. Jonathan Billerインサイダー | -988.00 | 493.01k | Automatic Disposition | 499.00 | 16.84k | -5.54% |
| 2026-02-13 | Mr. Jonathan Billerインサイダー | -2.99k | 1.46M | Sale to Issuer | 487.76 | 16.84k | -15.09% |
| 2026-02-13 | Dr. Sangeeta N. BhatiaIndependent Director | -266.00 | 133.00k | Automatic Disposition | 500.00 | 3.50k | -7.06% |
| 2026-02-13 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1.90k | 928.21k | Sale to Issuer | 487.76 | 20.14k | -8.63% |
| 2026-02-13 | Ms. Kristen C. AmbroseSenior VP & CAO | -1.39k | 679.45k | Sale to Issuer | 487.76 | 8.73k | -13.76% |
| 2026-02-10 | Mr. Charles F. WagnerExec. VP, COO & CFO | -3.05k | 1.43M | Sale to Issuer | 468.41 | 18.54k | -14.11% |
| 2026-02-11 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -466.00 | 214.56k | Automatic Disposition | 460.43 | 23.99k | -1.91% |
| 2026-02-10 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -2.14k | 1.00M | Sale to Issuer | 468.41 | 23.99k | -8.19% |
| 2026-02-10 | Mr. Amit K. SachdevExec. VP & Chief Patient and External Affairs Officer | -2.06k | 963.52k | Sale to Issuer | 468.41 | 79.12k | -2.53% |
| 2026-02-10 | Mr. Duncan J. McKechnieChief Commercial Officer, Head of North America Commercial & Exec. VP | -1.13k | 527.90k | Sale to Issuer | 468.41 | 21.81k | -4.91% |
| 2026-02-10 | Dr. Reshma KewalramaniCEO, President & Director | -8.30k | 3.89M | Sale to Issuer | 468.41 | 146.53k | -5.36% |
| 2026-02-11 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -2.02k | 930.53k | Automatic Disposition | 460.43 | 12.91k | -13.53% |
| 2026-02-10 | Dr. Mark BunnageExec. VP & Chief Scientific Officer | -1.13k | 527.90k | Sale to Issuer | 468.41 | 12.91k | -8.03% |
| 2026-02-10 | Dr. Carmen BozicExec. VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | -2.15k | 1.00M | Sale to Issuer | 468.41 | 41.86k | -4.87% |
| 2026-02-11 | Mr. Jonathan Billerインサイダー | -1.93k | 886.33k | Automatic Disposition | 460.43 | 20.82k | -8.46% |
| 2026-02-10 | Mr. Jonathan Billerインサイダー | -1.63k | 763.51k | Sale to Issuer | 468.41 | 20.82k | -7.26% |
| 2026-02-11 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -1.75k | 806.21k | Automatic Disposition | 460.43 | 22.05k | -7.36% |
| 2026-02-10 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -872.00 | 408.45k | Sale to Issuer | 468.41 | 22.05k | -3.80% |
| 2026-02-11 | Ms. Kristen C. AmbroseSenior VP & CAO | -1.38k | 633.55k | Automatic Disposition | 460.43 | 10.13k | -11.96% |
| 2026-02-10 | Ms. Kristen C. AmbroseSenior VP & CAO | -592.00 | 277.30k | Sale to Issuer | 468.41 | 10.13k | -5.52% |
| 2026-01-07 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -4.50k | 2.14M | Automatic Disposition | 474.99 | 21.35k | -17.41% |
| 2026-01-06 | Mr. Charles F. WagnerExec. VP, COO & CFO | -9.53k | 2.59M | Derivative Exercise and Sale | 189.38 - 461.00 | 15.29k | - |
| 2025-12-03 | Mr. Charles F. WagnerExec. VP, COO & CFO | -14.00k | 6.38M | Automatic Disposition | 451.00 - 461.00 | 15.29k | -47.80% |
| 2025-12-03 | Dr. Ourania TatsisExec. VP and Chief Regulatory & Quality Officer | -4.50k | 2.02M | Automatic Disposition | 449.99 | 25.85k | -14.83% |
| 2025-12-04 | Dr. Jeffrey Marc LeidenExecutive Chairman | 1.00 | 91.05 | Derivative Exercise and Retained Stock | 91.05 | 24.47k | 0.00% |
| 2025-12-03 | Dr. Jeffrey Marc LeidenExecutive Chairman | -63.78k | 23.13M | Derivative Exercise and Sale | 86.52 - 455.22 | 24.47k | - |
| 2025-12-03 | Mr. Jonathan Billerインサイダー | -347.00 | 155.80k | Automatic Disposition | 449.00 | 15.31k | -2.22% |
| 2025-11-19 | Mr. Lloyd A. CarneyIndependent Director | -800.00 | 0.00 | Other Disposition | - | 5.52k | -12.66% |
| 2025-11-17 | Dr. Edward Morrow AtkinsonEVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | -2.50k | 1.09M | Automatic Disposition | 434.58 | 16.85k | -12.92% |
| 2025-11-13 | Dr. Jeffrey Marc LeidenExecutive Chairman | -73.29k | 25.80M | Derivative Exercise and Sale | 86.52 - 442.00 | 24.47k | - |
| 2025-10-02 | Mr. Jonathan Billerインサイダー | -694.00 | 280.52k | Automatic Disposition | 404.21 | 15.65k | -4.25% |
| 2025-10-01 | Mr. Jonathan Billerインサイダー | -1.26k | 503.60k | Sale to Issuer | 400.00 | 15.65k | -7.44% |
| 2025-08-27 | Dr. Sangeeta N. BhatiaIndependent Director | -266.00 | 102.86k | Automatic Disposition | 386.69 | 3.77k | -6.59% |
| 2025-08-06 | Dr. Reshma KewalramaniCEO, President & Director | 10.00k | 3.90M | 買い | 389.08 - 389.95 | 115.97k | 9.44% |
| 2025-08-06 | Mr. Bruce I. SachsLead Independent Director | 5.00k | 1.95M | 買い | 389.36 - 389.84 | 45.00k | 12.50% |
| 2025-07-01 | Mr. Stuart A. Arbuckleインサイダー | -37.24k | 16.77M | Sale to Issuer | 450.23 | 63.51k | -36.97% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
